Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers

Mesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. As a result, mesothelin is an excellent candidate for tumor targeted immunotherapeutics. However, the antibodies against mesothelin that are available for clinical trials are of murine origin. These antibodies have the potential to elicit immune responses in patients, which may adversely affect the ability to provide patients with repeated doses. Thus, the clinical application of the antibodies may be limited.

In order to address the issue of immunogenicity in patients, NIH inventors have generated anti-mesothelin antibody variable fragments (Fv) of human origin. These antibody fragments (HN1 and HN2) have the ability to efficiently recognize mesothelin on the surface of numerous cancer cells. As a result, these antibody fragments represent an attractive therapeutic alternative to the murine anti-mesothelin antibodies currently being tested in clinical trials.

Potential Commercial Applications: Competitive Advantages:
  • Use as an antibody therapeutic for mesotheliomas, pancreatic tumors and ovarian tumors
  • Use in an immunotoxin therapeutic for mesotheliomas, pancreatic tumors and ovarian tumors
  • Diagnostic for the detection of mesothelin positive tumors
  • Research agent for the detection of mesothelin
  • Fully human antibody reduces potential immunogenicity, thereby allowing repeated dosing
  • Antibody specificity improves the therapeutic efficacy of the agent.

Development Stage:
Pre-clinical (in vivo)

Related Invention(s):


Mitchell Ho (NCI)  ➽ more inventions...

Ira Pastan (NCI)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 8460660 issued 2013-06-11
U.S. Filed Application No. 13/259,138

Ho M, et al. PMID 20635390
Hassan R, Ho M. PMID 17945478

Collaboration Opportunity:

Licensing and research collaboration

Licensing Contact:
John Hewes, Ph.D.
Phone: 240-276-5515

OTT Reference No: E-091-2009
Updated: Jun 29, 2017